While tumors with wild-type RAS genes are highly sensitive to anti-EGFR therapy, erroneous administration of cetuximab or panitumumab to patients with RAS-mutated CRC may facilitate tumor growth [5,6]. This evidence concerns the gene EGFR and neoplasm.